Relevance of Health Economics in the Medical Treatment of Breast Cancer: The View of the Professional Association of Practicing Gynecologic Oncologists e.V. (BNGO).
In this article, the position of the Professional Association of Practicing Gynecologic Oncologists e.V. (BNGO) on the health economics of medical breast cancer therapy is presented. The BNGO unites professionals and employees whose principal activity lies in highly specialized gynecologic oncology. In Germany, 139 specialists are united in 128 professional practices. According to § 12 of the Social Code, the oncological services provided by members must be 'sufficient, effective and economical; they must not exceed what is necessary'. People who are covered by statutory health insurance in Germany are entitled to sufficient benefits. Sufficient measures are measures that benefit the patient with breast cancer and have a positive effect on the course of the disease. In § 35b of the Social Code, the benefit of the patient is defined as 'improvement in health, shortening of the duration of illness, lengthening of lifespan, reduction of side effects and an improvement in the quality of life'. In the adjuvant situation, the ideal goal is healing; in the palliative situation, the most basic marker is overall survival, while surrogate markers are the progression-free interval, improved quality of life, or diminished symptoms. At the same time, the law on economic assessment stipulates 'appropriateness and reasonableness of reimbursement by the insured community'.
Gynecology/Oncology Focus Practice Fuerstenwalde, Germany.
Georg
G
Heinrich
Gynecology/Oncology Focus Practice Berlin, Germany.
Hindenburg
H
Hans-Joachim
Gynecology/Oncology Focus Practice Berlin, Germany.
Jörg
J
Schilling
Gynecology/Oncology Focus Practice Berlin, Germany.
Peter
P
Klare
Adjuvant therapy; Aromatase inhibitors; Chemotherapy; Systemic therapy; Therapy Costs